Advanced searches left 3/3

Germ Cell Tumor - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 15 August 2022

* If you want to update the article please login/register

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

At least 95% for patients with ovarian pure immature teratoma and pediatric patients with complete surgical resection and surveillance can achieve an overall survival rate of at least 9 percent at two years for pediatric, adolescent, and adult patients with stage I malignant germ cell tumors, with an overall survival rate of at least 95 percent at two years. When compared to cisplatin-based chemotherapy, it is estimated that the incidence of ototoxicity in children, adolescents, and young adults with standard risk germ cell tumors treated with carboplatin-based chemotherapy is similar to cisplatin-based chemotherapy. To prospectively determine the correlation of tumor marker decline with clinical outcomes in low- and standard risk germ cell tumor patients. Compare self-reported peripheral neuropathy and other patient-reported outcomes between children, adolescents, and young adults with standard risk germ cell tumor tumors treated with carboplatin-based chemotherapy as compared to cisplatin-based chemotherapy. Adolescent and Young Adult Hearing Screening instrument assesses the relationship between hearing loss as determined by audiometry and the effects of tinnitus. Objectives: To determine the prognostic significance of serum micro ribonucleic acid s in stage I testicular cancer patients by gathering clinical data and serum samples for future analysis. Outline: Patients with low-risk stage I, three ovarian immature teratoma, or stage I non-seminoma malignant germ cell tumors are screened and transferred to the standard risk group when eligibility requirements are fulfilled. On days 1-5, patients are also receiving etoposide IV for over 1-2 hours. Patients with a normal risk 2 are randomized into one of two arms.

Source link: https://clinicaltrials.gov/ct2/show/NCT03067181


A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

To determine the sensitivity of induction chemotherapy and WVSCI for localized NGGCT patients with a CR/PR, it is estimated. To determine the PFS and overall survival for localized NGGCT patients who experience a CR/PR and receive WVSCI, it is estimated that the PFS and overall survival for localized NGGCT patients who achieve a CR/PR and receive WVSCI. Patients with less than a CR/PR are now receiving high-dose chemotherapy with peripheral stem cell transplant rescue following Induction who later receive high-dose chemotherapy with peripheral stem cell rescue. To determine the PFS and OS for patients with less than a CR/PR. With testing as per the Children's Oncology Group Standardized Neuropsychological and Behavioral Battery, we can objectively assess and longitudinally model the cognitive, social, and behavioral characteristics of children and young adults with localized CNS NGGCT. On days 1-5 of cycles 2, 4, and 6, patients also receive ifosfamide IV over 60 minutes and etoposide IV over 60 minutes. Patients are referred to one of two programs based on induction chemotherapy response: Patients with radiographic CR/PR with marker normalization proceed to WVSCI. Patients with less than radiographic CR/PR without marker normalization have been admitted to second-look surgery. Patients receive etoposide IV and thiotepa IV over 3 hours on days -5 to -3 and undergo peripheral blood stem cell transplantation on day 0 within 6-8 weeks after completion of induction chemotherapy or second-look surgery. In the absence of disease progression or unacceptable toxicity, patients continue to receive radiation therapy QD for 5 days a week for 6 weeks.

Source link: https://clinicaltrials.gov/ct2/show/NCT04684368


A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

TIP: To compare the overall survival of patients treated with first-dose chemotherapy and autologous stem cell transplantation with TI-CE and TIP as the first salvage treatment for patients with relapsed or refractory GCT using TIP as the initial salvage therapy for patients with relapsed or refractory GCT. TIP: To determine the effective response rate in patients treated with first salvage CDCT using TIP in patients with TI-CE or first salvage CDCT with TIP as the first salvage chemotherapy TI-refractory GCT TI-CE TI-side TI-CE TI-mode TI-CE TI-refract TI-tile GCT with refractory GCT with refractory GCT with refract refractory GCT with refract refractory GCT with refractory GCT with refractory GCT with refract refractory GCT with refract refractory GCT with refractory GCT with refract.

Source link: https://clinicaltrials.gov/ct2/show/NCT02375204

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions